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Conclusions. We conclude that cAMP agonists stimulate thecAMP stimulates the in vitro proliferation of renal cyst epithe-
proliferation of ADPKD but not HKC epithelial cells throughlial cells by activating the extracellular signal-regulated kinase
PKA activation of the ERK pathway at a locus distal to receptorpathway.
tyrosine kinase. We suggest that the adenylyl cyclase signalingBackground. Cellular proliferation is a key factor in the
pathway may have a unique role in determining the rate of cystenlargement of renal cysts in autosomal dominant polycystic
enlargement in ADPKD through its actions to stimulate cellularkidney disease (ADPKD). We determined the extent to which
proliferation and transepithelial solute and fluid secretion.adenosine 39:59-cyclic monophosphate (cAMP) may regulate
the in vitro proliferation of cyst epithelial cells derived from
human ADPKD cysts.
Methods. Epithelial cells from cysts of individuals with
In autosomal dominant polycystic kidney diseaseADPKD and from normal human kidney cortex (HKC) of
(ADPKD), the progressive enlargement of cysts thatindividuals without ADPKD were cultured. The effects of ago-
nists and inhibitors on the rate of cellular proliferation and the develop in hundreds of individual renal tubules is
activation of extracellular signal-regulated kinase (ERK1/2) were thought to be a major factor in the decline of renal
determined. function that accompanies this disorder [1–3]. Within theResults. 8-Br-cAMP (100 mmol/L) stimulated the prolifera-
expanding tubule, a monolayer of epithelial cells formstion of cells from eight different ADPKD subjects to 99.0%
a barrier that is rate limiting for cyst enlargement. Theabove baseline; proliferation was inhibited by protein kinase
A (PKA) antagonists H-89 (97%) and Rp-cAMP (90%). For- renal cysts expand because of the proliferation of cyst
skolin (10 mmol/L), which activates adenylyl cyclase, increased wall epithelial cells and fluid accumulation within the
proliferation 124%, and receptor-mediated agonists arginine resultant cavity, primarily by transepithelial secretionvasopressin, desmopressin, secretin, vasoactive intestinal poly-
tied to chloride transport [4–6]. Adenosine 39:59-cyclicpeptide, and prostaglandin E2 stimulated proliferation 54.2,
56.3, 46.7, 37.1, and 48.3%, respectively. The mitogen extracel- monophosphate (cAMP) and agonists of the adenylyl
lular kinase (MEK) inhibitor PD98059 completely inhibited cyclase signaling pathway stimulate the secretion of sol-
ADPKD cell proliferation in response to cAMP agonists, but ute and fluid into the cysts by activating apical chloride
genistein, a receptor tyrosine kinase inhibitor, did not block
channels in the epithelial cells [7–9]. On the other hand,cAMP-dependent proliferation. cAMP agonists increased the
the potential role of cAMP in the proliferation of theactivity of ERK above control levels within five minutes. In
contrast to ADPKD, proliferation and ERK activity of cells cyst epithelial cells is unclear.
derived from normal HKC were not stimulated by cAMP ago- A proliferative action of cAMP in renal cystic disease
nists, although electrogenic Cl2 secretion was increased by has been suggested [10]. Cyst epithelial cells cultured in
these agonists in both ADPKD and HKC cell monolayers.
type 1 collagen matrix and treated with epidermal growth
factor (EGF) form fluid-filled microcysts. The rate of in
1 See Editorial by Grande, p. 1770 vitro microcyst expansion is accelerated by the addition
of cAMP or cAMP agonists [11, 12]. Levels of cAMPKey words: PKD, kidney, mitogen, adenylyl cyclase, fluid secretion,
ADPKD. are increased in kidney tissue and urine of mice (DBA/
2FG pcy/pcy) with a type of slowly progressive polycysticReceived for publication September 8, 1999
kidney disease, suggesting a role for the nucleotide inand in revised form November 11, 1999
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other hand, a recent study found evidence consistent by the Human Subject Committee of the Kansas Univer-
sity Medical Center under exemption 4.with an antimitogenic action of cAMP on the burst of
renal epithelial cell proliferation that follows the admin-
Bioelectric measurementsistration of toxic amounts of folic acid [14]. It would
appear, therefore, that the response of renal epithelial Monolayers of ADPKD and HKC cells, grown on Snap-
well membranes (Costar, Cambridge, MA, USA), werecells to increased levels of cAMP may depend on their
genetic backgrounds or state of maturation. mounted in modified using chambers as described pre-
viously [16, 17]. The chambers contained 4 mL of me-In the current study, we determined the respective roles
of the adenylyl cyclase and extracellular signal-regulated dium and were gassed and stirred with a slow stream of
5% CO2/95% O2. The medium used in these experimentskinase/mitogen activated protein kinase (ERK/MAPK)
pathways in mediating cellular proliferation and Cl2 was an isotonic Ringer’s solution that contained no se-
rum or serum components. The transepithelial potentialsecretion and the potential for cross-talk between these
pathways in epithelial cells cultured from human ADPKD difference (Vte), the short-circuit current (Isc), and mono-
layer resistance (Rte) were determined by techniquescyst walls and normal human kidney cortex (HKC). We
confirmed that cAMP promotes chloride-dependent described previously [16, 17]. The monolayers were
maintained in the short-circuited state, and the open-anion secretion by both ADPKD and HKC epithelial
cells; however, we found that cAMP stimulated cellular circuit voltage was determined at one- to five-minute
intervals. After a period of equilibration, measurementsproliferation of only the ADPKD cells and not the HKC
cells. Measurements of ERK activity are consistent with were made in sequential five-minute periods. Steady-
state Isc was recorded after the addition of agonists orthe interpretation that cAMP stimulates cellular prolifer-
ation of ADPKD cyst epithelial cells by activating the combinations of agonist and inhibitor to the basolateral
medium, typically after 20 minutes. In some cases, agentsERK/MAPK pathway.
were added to both apical and basolateral solutions.
METHODS Cell proliferation
Cell culture The Promega Cell titer 96 MTT Assay method, as
reported by Rankin et al, was used to determine theAutosomal dominant polycystic kidney disease and
normal HKC cells were obtained from discarded ne- relative rates of cell proliferation under different experi-
mental conditions [18]. This method, which measuresphrectomy specimens. The detailed methods have been
published [9, 11, 15]. Briefly, ADPKD cyst walls on the the optical density (O.D.) of a proliferation-dependent
reaction product, was found to correlate directly withcortex surface were cleaned of adherent fibrous tissue
and fat, and the dome of the cyst was cut free and di- direct determinations of cell number using the classical
hemacytometer technique. The relationship between cellgested in unsupplemented Dulbecco’s modified Eagle’s
medium (DMEM)/F12 containing collagenase (1 mg/mL; number and O.D. was linear, and r 2 was .0.98 for both
ADPKD and HKC cells (data not shown). To determineCooper Biochemicals, Malvern, PA, USA) to loosen the
epithelial cells from the basolateral matrix. The resultant the effect of agonists on the rate of proliferation, approxi-
mately 4000 cells were seeded into individual chamberscell suspension was centrifuged, and the pellet was rinsed
twice, resuspended, and plated in T-75 flasks in DMEM/ of a 96-well plate. The cells were incubated initially in
DMEM/F12 medium supplemented only with penicillin,F12 supplemented with 5% fetal bovine serum (FBS;
Hyclone, Logan, UT, USA), penicillin/streptomycin, and streptomycin, ITS, and 1% FBS. After 24 hours, the FBS
was reduced to 0.002% (ITS deleted) to arrest growth.5 mg/mL insulin, 5 mg/mL transferrin, and 5 ng/mL so-
dium selenite (ITS; Collaborative Biomedical Products, This small amount of serum was needed to potentiate
cell attachment to the plastic surface. Specific agonistsBedford, MA, USA) until the monolayers were approxi-
mately 75% confluent. These cultures were passaged no were added for another 48 to 72 hours. Preliminary stud-
ies were examined for desquamated cells, and no consis-more than twice. Cultures derived from cysts in this way
are relatively free of fibroblasts. tent effects of agonists were detected on the number of
cells in the supernantant. Inhibitors H-89, Rp-cAMP,Human kidney cortex cells were obtained from donor
kidneys that were unsuitable for transplantation or from genistein, and PD98059 were added for 30 minutes be-
fore the agonists.normal portions of kidneys that contained localized ade-
nocarcinoma. The cortex was minced, and cells were
Extracellular signal-regulated kinase activityreleased by digestion in collagenase and incubated in
DMEM/F12 supplemented with penicillin, streptomycin, We determined ERK activity by immune complex ki-
nase assay in the absence of stimulation by receptorITS, and 5% FBS until they were approximately 75%
confluent. After this, the cultures were handled identi- tyrosine kinase or protein kinase A (PKA) agonists and
after treatment with agonists. Cells were lyzed in 500cally. The kidney procurement protocols were approved
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mL of ice cold triton lysis buffer [TLB; 20 mmol/L Tris
(pH 7.4), 137 mmol/L NaCl, 25 mmol/L b-glycerophos-
phate, 2 mmol/L ethylenediaminetetraacetic acid (EDTA),
1 mmol/L sodium orthovanadate, 2 mmol/L NaHPO4,
1% Triton X-100, 10% glycerol, 1 mmol/L phenylmethyl-
sulfonyl fluoride, aprotinin (5 mg/mL), 2 mmol/L benzami-
dine, and 0.5 mmol/L dithiothreitol]. The procedure for
determining ERK activity of cell lysates was performed
as described previously for JNK1 using Protein A/G
PLUS agarose (Santa Cruz Biotechnology, Santa Cruz,
CA, USA) [19]. Briefly, 200 mg of clarified cellular ex-
tract were immunoprecipitated for two hours with gentle
rotation at 48C with a mixture of anti-ERK1 and -ERK2
antibodies (C-14 and C-16; Santa Cruz Biotechnology)
bonded to protein A/G PLUS agarose beads. Immune
complexes were washed and subjected to kinase assay
Fig. 1. Short circuit current (Isc) responses of autosomal dominantusing myelin basic protein (Sigma, St. Louis, MO, USA)
polycystic kidney disease (j; ADPKD) and human kidney cortex ( ;as a substrate in a buffer (40 mmol/L Tris, 20 mmol/L
HKC) monolayers to cAMP agonists. Isc was determined in the steady
MgCl2, 2 mmol/L MnCl2, and 0.5 mmol/L dithiothreitol) state and at least 20 minutes following the addition of the agonist.
Baseline Isc (mA/cm2), Vte (mV), and Rte (ohm cm2) values for 39in the presence of radioactive-labeled [g-32P]-ATP (1 mCi/
ADPKD and 30 HKC were 3.6 6 0.2 and 6.1 6 0.3, –2.1 6 –0.2 andmmol/L). The reaction was performed at 308C for 30
–5.2 6 0.4 and 509 6 51 and 751 6 32, respectively. 8-Br-cAMP (100
minutes and stopped with sodium dodecyl sulfate (SDS) mmol/L), forskolin (10 mmol/L); AVP, arginine vasopressin (100 mU/
mL); DDAVP, desmopressin (100 mU/mL); VIP, vasoactive intestinalsample buffer. Heated samples (95 to 1008C) were sepa-
polypeptide (1 mmol/L); PGE2, prostaglandin E2 (25 ng/mL). The num-rated on a 15% SDS-polyacrylamide gel electrophoresis
ber of monolayers is shown in parenthesis. Bars represent means 6
(PAGE), and the kinase activity of ERK1/2 was quanti- SEM. Abbreviations are in the Appendix.
tated using PhosphorImager analysis of the labeled bands.
ERK1/2 activity was determined at periodic intervals
for up to 120 minutes after adding EGF, 8-Br-cAMP, or
ReagentscAMP agonists [arginine vasopressin (AVP), prostaglan-
din E2 (PGE2), secretin, vasoactive intestinal polypep- 8-Br-cAMP, forskolin, AVP, DDAVP, secretin, VIP,
PGE2, EGF, and genistein were obtained from Sigma.tide (VIP)] to the medium. EGF, AVP, desmopressin
(DDAVP), PGE2, secretin, and VIP were obtained from PD98059 was purchased from New England Biolabs Inc.
(Beverly, MA, USA).Sigma. DDAVP was purchased from Rhone-Poulenc
Rorer Pharmaceuticals (Collegeville, PA, USA).
Statistics
Western blot analysis Mean and SEM were calculated as usual, and levels
of significant difference (P , 0.05) were determined byERK1/2 immunoblots were performed as follows. Ali-
quots (20 mg) of cellular proteins were resolved by 10% unpaired t-test.
SDS-PAGE. The transfer of proteins from gels to nitro-
cellulose membranes was carried out at 48C. After trans-
RESULTS
fer, the nitrocellulose membranes (Midwest Scientific,
Bioelectric measurements in autosomal dominantSt. Louis, MO, USA) were blocked with 5% dry milk
polycystic kidney disease and human kidneyin TBS-T (20 mmol/L Tris-HCl, pH 8.0, 137 mmol/L
cortex monolayersNaCl, and 0.05% Tween 20). Blocking was carried out
overnight at 48C. Blocked membranes were then incu- Confluent monolayers of ADPKD cells from five sub-
jects developed stable lumen negative transepithelialbated with a 3:10,000 dilution of the ERK1/2 primary
antibodies (C-14 and C-16; Santa Cruz Biotechnology) voltage (Vte), resistance (Rte), and short-circuit current
(Isc) in control medium as reported previously (Fig. 1)in 5% dry milk in TBS-T for an hour. Membranes were
then washed three times with TBS-T and incubated with [11, 16, 17]. HKC monolayers from three subjects devel-
oped baseline lumen negative Vte, Rte, and Isc levelsa 1:10,000 dilution of the secondary antirabbit horserad-
ish peroxidase antibody (Sigma) diluted in 5% dry milk that were significantly greater than the ADPKD mem-
branes (P , 0.001). The mechanism of this differencein TBS-T for 60 minutes. The membranes were washed
three times with TBS-T and ERK protein visualized us- in absolute baseline values between ADPKD and HKC
membranes was not explored. Consistent with previousing an enhanced chemiluminescence system (ECL; Am-
ersham Life Sciences, Arlington Heights, IL, USA). reports, treatment with 8-Br-cAMP or forskolin, which
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Table 1. Isc (mamp/cm2) response of ADPKD and HKC to H-89
Forskolin Forskolin 1 H89
# Baseline D Forskolin D H-8910 lmol
ADPKD 4 1.4 60.4 5.060.6 1.160.3a 3.760.4 23.960.6
HKC 4 7.0 60.5 11.060.7 6.560.8a 4.060.3 24.560.4
a Different from forskolin alone, P , 0.05
activates adenylyl cyclase, rapidly increased Isc and Vte
in all of the monolayers in which these agents were tested
[4, 11, 16, 17]. We used this feature as a means of profiling
ADPKD cells in relationship to HKC cells. After adding
8-Br-cAMP (100 mmol/L), Isc typically increased to a
peak value within five minutes and then fell within ten
minutes to levels higher than the initial baseline that
remained stable for as long as 60 minutes. We have
previously shown that the increase in Isc in response to
cAMP agonists is due to transepithelial Cl2 secretion
[11]. In the current study, forskolin caused a sustained
increase in Isc and hyperpolarized Vte in both ADPKD
and HKC monolayers, indicating that both types of cells
have functional adenylyl cyclase that is coupled to net
chloride transport (Fig. 1).
We also tested several hormones and an autacoid,
Fig. 2. Effect of EGF (25 ng/mL) and cAMP agonists on the prolifera-
PGE2, to profile receptor-mediated activation of ade- tion of ADPKD cells. Cells were incubated in minimal growth medium
(indicated by the zero baseline) followed by the selective addition ofnylyl cyclase in ADPKD and HKC cells. AVP, which
agonist for 48 hours. Concentrations were the same as in Figure 1activates both V1 and V2 receptors, increased Isc in both [including in addition secretin, 1 mmol/L, and isobutylmethylxanthine
ADPKD and HKC monolayers (Fig. 1). DDAVP, which (IBMX), 100 mmol/L]. Bars indicate the mean 6 SEM change in cell
number [quantitated by the measurement of optical density (O.D.)]selectively activates V2 receptors, increased Isc to about caused by the agonist as a percentage of the number of cells in the
the same extent as AVP in both types of cells. V2 receptor minimal growth medium. In parenthesis, the numerator is the number
of determinations, and the denominator is the number of differentactivation is mediated through an increase in cAMP.
ADPKD kidneys. Differences from untreated cells incubated in minimalVIP had similar effects on Isc in the two types of cells. growth medium are: *P , 0.001 and 1P , 0.01.
PGE2 increased Isc to higher levels in ADPKD than in
HKC cells. Secretin was evaluated in a few monolayers
and was found to stimulate Isc in both ADPKD and
liferation 53.7% (Fig. 2). The addition to control mediumHKC (data not shown). Taken together, these results
of a permeable and phosphodiesterase-resistant deriva-show that monolayers derived from ADPKD and normal
tive of cAMP (100 mmol/L 8-Br-cAMP) increased thehuman kidneys respond similarly to a variety of receptor-
rate of cellular proliferation 99.0%, exceeding thatmediated agonists of adenylyl cyclase.
caused by EGF. Forskolin (10 mmol/L) stimulated cellu-To confirm a role for endogenous cAMP on Isc follow-
lar proliferation 124%, also well above the EGF re-ing the addition of forskolin, we incubated ADPKD and
sponse. Isobutylmethylxanthine (IBMX; 100 mmol/L),HKC monolayers with H-89, which inhibits PKA (Table
which inhibits phosphodiesterase, stimulated prolifera-1). H-89 blocked the effect of forskolin to stimulate Isc
tion 21.1%. Receptor-mediated agonists of adenylyl cy-
in both ADPKD and HKC cells. clase (100 mU/mL AVP, 100 mU/mL DDAVP, 1 mmol/L
secretin, 1 mmol/L VIP, and 25 ng/mL PGE2) also stimu-Proliferation of autosomal dominant polycystic kidney
lated the rate of cellular proliferation 54.2, 56.3, 46.7,
disease cells 37.1, and 48.3%, respectively.
The total number of cells in each of four wells in- In the Promega proliferation assay system, agonists
creased from approximately 4000 to 6000 after 48 hours were added to subconfluent cells. To determine whether
in control medium containing small amounts of FBS EGF and forskolin would stimulate the proliferation of
(0.002%) and no other growth agonists. EGF (25 ng/mL), confluent monolayers, we incubated ADPKD cells in
1% FBS for 96 hours and then reduced the FBS to 0.1%which activates receptor tyrosine kinase, stimulated pro-
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for 24 hours before adding EGF (25 ng/mL) or forskolin
(10 mmol/L) for an additional 48 hours. The number of
cells released from the plastic chambers by trypsin was
counted manually using an hemacytometer. There were
34,562 6 969 cells per well (mean 6 SEM) in the control
medium and 38,133 6 733 and 38,309 6 803 cells per
well in the EGF- and forskolin-treated wells, respec-
tively. The increments in total cell number caused by
EGF and forskolin were significant (P , 0.05).
To determine whether adenylyl cyclase-dependent ac-
tivation of PKA is involved in mediating the proliferative
action of cAMP agonists, we preincubated the cells with
PKA inhibitors H-89 and Rp-cAMP and then added
forskolin together with the inhibitors (Fig. 3). H-89 and
Rp-cAMP completely blocked the effect of forskolin to
stimulate the proliferation of ADPKD cells, indicating
that PKA activation was instrumental in promoting cell
proliferation of ADPKD cells (Fig. 3A). To determine
the potential role of the ERK/MAPK pathway, we prein-
cubated ADPKD cells with either PD98059, which pre-
vents the activation of mitogen extracellular kinase
(MEK), or genistein, a receptor tyrosine kinase inhibitor
(Fig. 3B). In pretreated cells, PD98059 completely
blocked the proliferative effect of forskolin, whereas
genistein had no significant effect. Similar results were
observed after the addition of 8-Br-cAMP instead of
forskolin plus the inhibitors (Fig. 3C). H-89, Rp-cAMP,
and PD98059 blocked the proliferative response of
ADPKD cells to the cyclic nucleotide, but genistein had
no effect, suggesting that cAMP increased the activity
of MEK1 but at a locus distal to the activation of receptor
tyrosine kinase.
We tested the hypothesis that EGF stimulates cellular
proliferation by activating receptor tyrosine kinase in
ADPKD cells. Genistein, which had no effect on the
proliferation caused by forskolin and 8-Br-cAMP, sig-
nificantly diminished the proliferation caused by EGF
(Fig. 4). PD98059, which had blocked the proliferative
effects of forskolin and 8-Br-cAMP, also blocked the
action of EGF to stimulate proliferation of ADPKD cells
(Fig. 4). The findings illustrated in Figures 3 and 4 may
be interpreted to indicate that ADPKD cell proliferation
is sensitive to mediators of both the adenylyl cyclase and
ERK/MAP kinase signal transduction systems with the
possibility of cross-talk between the two pathways.
Since cAMP actually inhibits Raf activation within the
MAP kinase pathway in many types of cells [20–24], the
Fig. 3. Effect of inhibitors on proliferation of ADPKD cells. (A) Effect of H-89 (10 mmol/L) and Rp-cAMP (250 mmol/L) on response to forskolin
(10 mmol/L). Results represent 28 determinations in 7 different ADPKD kidneys. Differences between forskolin 1 H-89 vs. forskolin, forskolin 1
Rp-cAMP vs. forskolin, and H-89 vs. minimal growth medium are shown. *P , 0.001. (B) Effect of genistein (40 mmol/L) and PD98059 (50 mmol/L).
The results represent 12 determinations in three different ADPKD kidneys. The difference between forskolin 1 PD98059 vs. forskolin is shown.
*P , 0.001. (C) Effect of inhibitors on 8-Br-cAMP–stimulated (100 mmol/L) proliferation of ADPKD cells. H-89 (10 mmol/L), Rp-cAMP (250
mmol/L), genistein (40 mmol/L), and PD98059 (50 mmol/L) were added to cells treated with 8-Br-cAMP. The results represent eight determinations
in two different ADPKD kidneys. Differences from 8-Br-cAMP are *P , 0.001.
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Fig. 4. Effect of inhibitors on EGF-stimulated proliferation of
ADPKD cells. H-89 (10 mmol/L), Rp-cAMP (250 mmol/L), genistein
(40 mmol/L), and PD98059 (50 mmol/L) were added to cells treated
with EGF (25 ng/mL). The results represent eight determinations in
two different ADPKD kidneys. Differences from EGF are *P , 0.001.
observation that PD98059 blocked the individual effects
of cAMP and EGF to increase the proliferation of
ADPKD cells was surprising, and suggested that the
adenylyl cyclase and receptor tyrosine kinase signaling
pathways may converge at a point in the ERK/MAP
kinase cascade distal to Raf. We tested this hypothesis
by evaluating the effect on cell proliferation of adding
forskolin and EGF together in comparison to adding
either compound alone. Maximally effective concentra-
tions of forskolin (10 mmol/L) and EGF (25 ng/mL)
Fig. 5. Combined effects of EGF and forskolin on proliferation ofadded together caused the rate of cell proliferation to
ADPKD and HKC cells. (A) ADPKD cells were treated with EGF (25
increase above that of either agonist alone (Fig. 5A). ng/mL), forskolin (10 mmol/L), or a combination of EGF and forskolin.
Numbers are the percentage change from minimal growth medium.This finding suggested that cAMP probably does not
The results represent 12 determinations in three different ADPKDinhibit Raf in ADPKD cells and that the nucleotide may
kidneys. Differences from minimal growth medium are *P , 0.001. (B)
activate the ERK/MAPK pathway distal to Raf-1. HKC cells were treated with EGF (25 ng/mL), forskolin (10 mmol/L),
or a combination of EGF and forskolin. The results represent eightTo determine more directly the role of the ERK/
determinations in two different HKC kidneys. Differences from EGFMAPK pathway in cAMP-stimulated cell proliferation, are *P , 0.001.
we examined the effect of forskolin and cAMP agonists
on ERK1/2 activity in ADPKD cells from two different
subjects in which cAMP had been shown to stimulate each sample, indicating that kinase activity, rather than
cellular proliferation. Following the addition of for- protein abundance, was increased by 8-Br-cAMP, c-AMP
skolin, the amount of myelin basic protein phosphory- agonists, and EGF in ADPKD cells.
lated by ERK1/2 was increased 1.5-fold within 5 minutes
Proliferation of human kidney cortex cellsand 2.5-fold after 15 minutes (ADPKD #138; Fig. 6A).
ERK1/2 activity remained elevated above control levels In the absence of specific agonists, the HKC total cell
for as long as 120 minutes after the addition of forskolin. number increased from approximately 4000 to 4800 in
8-Br-cAMP and receptor-mediated agonists of cAMP 72 hours, reflecting a slower rate of baseline proliferation
also increased ERK1/2 activity above baseline (ADPKD than ADPKD cells. The addition of EGF increased cellu-
#136; Fig. 6B). EGF increased ERK1/2 activity but to lar proliferation as did FBS (Fig. 7A). In contrast to
a lesser extent than the cAMP agonists. Western blot ADPKD cells, however, neither 8-Br-cAMP nor any of
analysis of ADPKD #136 (Fig. 6C) confirmed that a the cAMP agonists increased cellular proliferation. In
fact, 8-Br-cAMP, forskolin, IBMX, AVP, DDAVP, se-similar amount of ERK1/2 protein had been added in
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Fig. 6. ERK1/2 activity in ADPKD cells. (A) ADPKD 138 cells were
placed in minimal growth medium for 24 hours, and then forskolin or
ethanol (the carrier for forskolin) was added for the indicated times.
The ratios of ERK activity in cells treated with forskolin compared
with ethanol only were 1.5, 2.5, 2.3, 2.1, and 2.6 determined by Phospho-
Imager analysis of both bands for the respective times. (B) ADPKD
136 cells were placed in minimal growth medium for 24 hours and
then incubated for 15 minutes with various agonists. Concentrations of
agonists were the same as in Figure 2. Agonist to carrier ERK activity
ratios for forskolin, EGF, 8-Br-cAMP, AVP, DDAVP, secretin, VIP,
and PGE2 were 8.8, 2.2, 6.5, 2.0, 2.0, 5.2, 4.4, and 3.5, respectively. (C)
Western blot analysis of ADPKD 136 cell lysates used for the ERK
assay in (B). ERK1 and ERK2 isoforms are indicated.
Fig. 7. Effect of EGF (25 ng/mL), FBS (1%), cAMP agonists, and
inhibitors on the proliferation of HKC cells. (A) Agonists. Cells were
incubated in minimal growth medium followed by the selective addition
of agonist for 72 hours using concentrations listed in Figures 1 and 2.
cretin, VIP, and PGE2 decreased the rate of HKC prolif- In parenthesis, the numerator is the number of determinations, and the
denominator the number of different HKC kidneys. Differences fromeration below baseline.
minimal growth medium are *P , 0.001 and 1P , 0.01. (B) EffectThe proliferative action of EGF was inhibited by both
of genistein (40 mmol/L) and PD98059 (50 mmol/L) on proliferation
genistein and PD98059, which is consistent with roles stimulated by EGF. Differences between EGF 1 genistein vs. EGF,
genistein vs. minimal growth medium, and EGF 1 PD98059 vs. EGFfor both the receptor tyrosine kinase and MAP kinase
are *P , 0.001. The difference between PD98059 and minimal growthpathways in HKC cells (Fig. 7B). However, in contrast
medium is 1P , 0.01.
to ADPKD cells, in which forskolin augmented the pro-
liferative action of EGF, the adenylyl cyclase agonist
diminished the effect of EGF to stimulate proliferation
in HKC cells (Fig. 5B). Pretreatment with the specific MEK inhibitor PD98059
In HKC cells from two subjects without ADPKD had no significant effect on the forskolin-mediated in-
(HKC 105 and 129), ERK1/2 activity was stimulated by crease in Isc across ADPKD monolayers (Table 2). The
EGF and FBS, but forskolin and other cAMP agonists effect of PD98059 on forskolin-dependent Isc was not
had no apparent effect (Fig. 8A, B). Western blot analy- tested in HKC cells.
sis of HKC #105 (Fig. 8C) confirmed that a similar
amount of ERK1/2 protein had been added in each sam-
DISCUSSIONple. These findings reinforce the hypothesis that intracel-
Epithelial proliferation in cyst walls is a major factorlular components that link activated PKA to the ERK/
underlying progressive renal enlargement in ADPKD.MAPK pathway in ADPKD cells are lacking or are un-
derrepresented in normal HKC cells. This amplification of the surface area increases the capac-
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without cystic disease. In those studies, cAMP inhibited
the action of EGF to stimulate proliferation of MDCK
cells, an established renal cell line derived from distal
tubule elements, and was thought to exert this effect by
inhibiting Raf-1, a key protein that translates signals
from the receptor tyrosine kinase pathway to the MAP
kinase cascade [27]. Similarly, cAMP inhibited the MAP
kinase pathway in rat mesangial cells and diminished the
proliferative response to EGF [23, 24]. In a recent study,
the epithelial proliferative response to acute tubular in-
jury caused by the infusion of toxic amounts of folic acid
to rats was blocked by the administration of phosphodi-
esterase inhibitors, which elevate tissue levels of cAMP
[14]. In the current report, we found that cells cultured
from normal HKC were not stimulated by cAMP ago-
nists; rather, the rate of proliferation was diminished by
these agents consistent with the response observed in
glomerular mesangial cells and epithelial cells of geneti-
cally normal animals after tubular injury with folic acid
Fig. 8. ERK1/2 activity in HKC cells. (A) HKC 129 cells were placed (Fig. 7). Moreover, stimulation of cAMP production di-in minimal growth medium for 24 hours, and then specific additions
were made for 15 minutes. Agonist to carrier ERK activity ratios for minished the proliferative response to EGF in HKC cells
EGF, EGF-repeat, forskolin, AVP, secretin, VIP, PGE2, and FBS 1% from individuals without ADPKD, an effect that is con-
were 2.6, 3.0, 1.1, 1.0, 1.0, 1.2, 1.1, and 4.7, respectively. (B) HKC 105
sistent with the inhibition of the MAP kinase pathwaycells were placed in minimal growth medium for 24 hours. After the
addition for 15 minutes of forskolin, EGF, 8-Br-cAMP, AVP, DDAVP by the nucleotide, possibly at Raf-1. In this context, it
secretin, VIP, and PGE2 in concentrations listed in Figure 1 and 2, should be noted that Heasley et al found that neitheragonist to carrier ERK activity ratios determined by PhosphoImager
vasopressin nor b-adrenergic agonists activated MAPanalysis were 0.4, 4.6, 0.4, 0.4, 0.5, 0.9, 0.8, and 0.3, respectively. (C)
Western blot analysis of HKC 105 cell lysates used for the ERK assay kinase in medullary cells cultured from normal rat kidney
in (B). ERK1 and ERK2 isoforms are indicated. despite clear stimulation of cAMP-dependent protein
kinase [28]. On the basis of these findings, it appears
that the proliferative response to cAMP of epithelial
cells derived from ADPKD cysts is distinctly differentity of the cysts to accommodate fluid that drains into
from that of otherwise genetically normal tubule cells.them from afferent tubule segments and transepithelial
There are important similarities and differences be-fluid secretion [2, 4, 5]. The factors that regulate epithe-
tween cultured ADPKD and HKC cells.lial growth are incompletely understood in ADPKD.
Previous studies of cyst epithelial cell proliferation had
Similaritiesimplicated EGF as a major agonist [25, 26]. A role for
Both types of cells are derived from renal cortex andcAMP in proliferation had been suggested but not clearly
grow on plastic dishes and permeable membranes asdefined (abstract; Hanaoka et al, J Am Soc Nephrol
morphologically similar epithelial monolayers [15, 17].7:1656, 1996) [2, 10, 12]. In the current study, we present
The cells react strongly to distal nephron markers (cyto-evidence that the direct application of a permeable form
keratin antibodies AE1/AE3, epithelial membrane anti-of cAMP or one of several receptor-mediated agonists of
gen, and Archis hypogaea lectin; unpublished observa-adenylyl cyclase stimulates the proliferation of epithelial
tion of the authors) [15]. Both types of cells formcells cultured from human ADPKD cysts (Fig. 2). cAMP
microcysts in type 1 collagen gels upon treatment withagonists stimulated proliferation in every case, although
EGF [11, 15]. ADPKD and HKC monolayers generatethe magnitudes of the responses were variable from indi-
stable transepithelial electrical resistance, lumen-nega-vidual to individual. Interference with the proliferative
tive voltage, and baseline short-circuit current (Fig. 1).effect of cAMP by PKA inhibitors H-89 and Rp-cAMP
Isc measurements indicated that adenylyl cyclase of bothis consistent with a role for the nucleotide in mediating
types of cells is stimulated similarly by a panel of agonistsADPKD cellular proliferation in vitro (Fig. 3).
(Fig. 1) and that the effect can be diminished by inhib-We found that cAMP and EGF had complementary
iting PKA with H-89 (Table 1). Thus, the generation ofand additive effects on the rate at which ADPKD cells
cAMP and the effect of the nucleotide to stimulate netproliferate (Fig. 5A). This finding differed with previous
chloride secretion appear to be functionally active inreports that explored the in vitro and in situ interaction
of cAMP and EGF in renal cells derived from animals both types of cells. We found no evidence to suggest
Yamaguchi et al: Cell proliferation in polycystic kidney disease1468
Fig. 9. Schematic diagram illustrating the hypothesis. (A) cAMP stimulates the proliferation of ADPKD cells by activating the MAP kinase
pathway at MEK through the intermediacy of unknown elements indicated by (?). Src, Grb, Sos, and Ras are proximal components of a receptor
tyrosine kinase pathway that interacts with the MAP kinase cascade at Raf-1. According to this hypothesis, stimulation of increased intracellular
levels of cAMP, either by receptor-ligand binding, relief of Gi inhibition of adenylyl cyclase, inhibition of phosphodiesterase, or combinations of
these actions, promotes the enlargement of cysts by stimulating both the proliferation of the cells through cross-talk with the ERK(MAPK)
pathway and the transepithelial secretion of Cl2 into the cyst lumen through cAMP-regulated channels. (B) In HKC cells, cAMP stimulates solute
and fluid secretion but may diminish cellular proliferation by inhibiting the activation of MEK by Raf-1.
Table 2. Lack of PD98059 effect on Isc response of ADPKD monolayers to forskolin
PD98059
Forskolin pretreatment PD98059 D Forskolin 1
# Baseline 10 lmol/L 50 lmol/L 1 Forskolin D Forskolin PD98059
8 3.660.5 6.060.8 3.760.8 5.961.3 2.460.3 2.260.5
that ADPKD cells were more or less responsive to cAMP Differences
agonists than HKC cells. On the other hand, striking differences between
The integrity of the receptor tyrosine kinase and MAP ADPKD and HKC cells appeared in the capacity of for-
kinase signal transduction pathways also appeared to be skolin and cAMP agonists to activate the ERK/MAPK
maintained in light of the fact that after treatment with cascade and to stimulate proliferation. Forskolin increased
EGF, the increased cellular proliferation of ADPKD the cellular activity of ERK1/2 in ADPKD cells from
and HKC cells could be blocked by the receptor tyrosine the two subjects in which kinase activity was measured,
kinase inhibitor genistein or the MEK1 inhibitor PD98059 whereas this adenylyl cyclase agonist had no effect on
ERK1/2 activity in HKC cells from two subjects without(Figs. 4 and 7).
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Fig. 9. Continued.
ADPKD (Figs. 6 and 8). Since the ADPKD proliferation responses to forskolin and 8-Br-cAMP were completely
abrogated by the PKA inhibitor H-89 (Fig. 3). Thus, aresponse to forskolin was blocked by the MEK inhibitor
PD98059 and the addition of forskolin did not inhibit guanine nucleotide exchange factor would seem to have
a minor, if any, role at all in translating the cAMP signalthe proliferation response to EGF in ADPKD cells, it
seems reasonable to suggest that MEK may be a site at to the ERK/MAPK cascade in ADPKD cells. The same
may be said for a direct effect of activated PKA on p70which cAMP, or a mediator activated by this nucleotide,
engages and activates the ERK/MAPK cascade. 6SK [31], cyclin D [32, 33], or cAMP response element
proteins (CREB) [34]. These pathways to cellular stimu-To the extent that these results reflect the behavior
of cyst epithelial cells from all ADPKD subjects, they lation mediated by activated PKA are probably of rela-
tively minor significance in ADPKD cells given the factraise the intriguing possibility that acquired or up-regu-
lated proteins in ADPKD cells may bypass the ordinary that the MEK inhibitor eliminated the proliferative re-
sponse to forskolin and 8-Br-cAMP (Fig. 3). On theinhibition of Raf-1 by increased levels of cAMP and may
provide a stimulatory link to MEK. One candidate for other hand, PKA may indirectly activate MEK through
the intermediacy of Rap-1 and B-Raf, as has recentlythis putative linkage process is the newly discovered gua-
nine nucleotide exchange factor (Epac), which mediates been described in PC-12 and COS cells, which are stimu-
lated to proliferate by cAMP [35, 36]. B-Raf is morethe direct stimulation by cAMP of small G proteins such
as Rap-1, thereby by-passing PKA [29, 30]. However, abundant than Raf-1 in PC-12 and COS cells. In these
cells, PKA activates Rap-1, which in turn sequentiallythis mechanism seems an unlikely explanation for the
action of cAMP in ADPKD cells, since the proliferative activates B-Raf and MEK [35, 36]. Further studies are
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mechanism in ADPKD cells that would account for the
capacity of cAMP to stimulate proliferation in ADPKD
APPENDIXcells, possibly because of an altered state of cellular dif-
Abbreviations used in this article are: ADPKD, autosomal dominantferentiation consequent to the mutations in polycystin
polycystic kidney disease; AVP, arginine vasopressin; cAMP, adeno-[37–40]. The fact that the combination of EGF and for- sine 39:59-cyclic monophosphate; CREB, cAMP response element pro-
skolin caused an additive increase in cellular prolifera- teins; DDAVP, desmopressin; ECL, enhanced chemiluminescence;
EDTA, ethylenediaminetetraacetic acid; EGF, epidermal growth fac-tion, not inhibition (Fig. 5A), suggests that Raf-1 may
tor; ERK, extracellular signal-regulated kinase; FBS, fetal bovine se-be diminished or resistant to inhibition by cAMP in
rum; HKC, human kidney cortex; IBMX, isobutylmethylxanthine; ITS,
ADPKD cells. We propose that PKA “bypasses” the insulin/transferrin/sodium selenite; Isc, short-circuit current; MAPK,
mitogen-activated protein kinase; MEK, mitogen extracellular kinase;usual inhibition of Raf-1 and activates MEK through
O.D., optical density; PGE2, prostaglandin E2; PKD, polycystic kidneyas yet undetermined intermediates, thereby leading to
disease; PKA, protein kinase A; Rte, monolayer resistance; TLB, triton
downstream stimulation of cell division. On the other lysis buffer; VIP, vasoactive intestinal polypeptide; Vte, transepithelial
potential difference.hand, in normal cells, the stimulatory effects of elevated
cAMP levels may be minimized in relationship to the
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